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INTRODUCTION
In Europe, people have become increasingly aware of the risks associated with the release of biological products. There is a fear that soils and water might become contaminated by genetically-modified organisms (GMOs). The main question is whether the development and release of new biologicals will cause any adverse reactions to biological populations or human health. For the first step, the analysis of this risk, it is essential to determine which methods are effective in analysing such risks (1) . One main point is the national and international standardisation of risk assessment methodology, at least for qualitative risk assessment (2) . Model and method should be seen as a whole, because only internationally-accepted scientific methods can be part of a good working model. Qualitative risk assessment should enable national control authorities to make a decision early in the registration process of innovatory biological products (4) . From 1995 onwards, three registration procedures will be available in the European Union (EU):
-A centralised EU registration procedure, reserved for high-technology products and for all innovatory biologicals. Such EU-wide authorisation is valid for all Member States.
-A decentralised procedure based on the principle of mutual recognition. The number of Member States covered is variable. This procedure will apply to the majority of biological products manufactured by conventional methods.
-A national registration procedure, limited -in principle -to applications of local interest.
The evaluation of applications during a centralised EU registration procedure will be the responsibility of the Committee for Veterinary Medicinal Products (CVMP) within the European Agency for the Evaluation of Medicinal Products (EMEA). The decision-maker has to decide quickly, however, once a timetable has been established by the CVMP. Rapid models of risk assessments for biologicals or related products must therefore be available as a basis for the deliberate release of new vaccine strains into the environment.
NATURE AND NOMENCLATURE OF BIOLOGICALS
Biological products are regarded as those which cannot be completely characterised by chemical and physical tests alone. To ensure the quality, safety and efficacy of these products as far as possible, it is essential that they be adequately controlled by validated methods. Information on the quality and purity of seed cultures and cell substrates, and on the effectiveness of purification and test methods, will be required by national authorities or by the CVMP within the EMEA. Veterinary vaccines or immunological veterinary medicinal products (IVMPs) can consist of GMOs or may contain conventional vaccine strains (non-GMOs). A distinction is also observed between viral, bacterial and parasitic vaccines with killed ('inactivated') or live antigens. If the inactivation process is validated and controlled in-process, killed vaccines are generally safer and their environmental risk is very low. Conventional live vaccines are based on attenuated strains which are no longer pathogenic or on strains with natural mutations. The environmental risks associated with live vaccines are higher than with killed vaccines.
RELATED PRODUCTS
In addition to biological products, consideration will also be given here to certain 'related' products, so-called 'inducers', i.e. biological response modifiers (BRMs), which induce non-specific protection in humans and animals. Biological and chemical inducers can be distinguished, but to date biological inducers appear easier to develop than chemical inducers. The functional basis of all inducers is the activation of the lymphopoietic system -such as T-dependent lymphocytes, killer-cells and helper-cells -accompanied by the induction of interferon. The rate of activity induced by BRMs may differ according to the means of application. Much research is being performed to gain a better understanding of cell-mediated immunity. The following important facts are now known:
-The mechanism involved in cell-mediated immunity is distinctly different from that for humoral immunity.
-The relative importance of humoral immunity and cell-mediated immunity varies, depending on the disease.
In detail, the induction of 'paramunity' -which covers 'non-specific immunity' and 'non-specific resistance' (3) -includes induction of interferon, increase in the rate of phagocytosis and lymphocyte activation. Paramunity is the protection of an organism against a variety of infections; this protection develops within a short period of time and is not specific against certain germs of antigens. Like IVMPs, BRMs can contain killed or live antigens with different environmental risks (Table I) . 
EUROPEAN RISK POLICY
Those who formerly advocated a 'zero-risk' policy have changed their minds in recent years, following the realisation that such a policy is very expensive, nearly impossible to implement and often unnecessary. Instead of a zero-risk policy, an assessed-risk policy accompanied by risk assessment, risk management and risk communication has been accepted in Europe and throughout the world. European Economic Community (EEC: now EU) Directives 90/220 EEC, 91/412 EEC and 92/18 EEC can be seen as essential steps from a zero-risk policy to an assessed-risk policy in the early 1990s. Additional regulations and recommendations are given by the monographs of the European Pharmacopoeia (EP) for many vaccines against contagious animal diseases (Fig. 1 ).
The majority of industrial applications for new IVMPs in Europe will use non-GMOs and GMOs of intrinsically low risk, which warrant only minimal containment. In 1994, various drafts of risk assessment regulations were discussed by working parties of the CVMP. Titles include the following: This last draft refers to EU Council Regulation 2309/93, on the licensing of IVMPs which contain or consist of GMOs. EU Council Regulation 2309/93 covers risks of damage to human health and to the environment. Potential hazards of the commercial use of GMOs are expected to be of the same nature as for non-GMOs and BRMs. Such undesired reactions can be of an infectious, toxic or allergenic nature, and may also include environmental effects. For registration authorities and their decisions, the estimation of risks and the likelihood of hazards are of great importance (Table II) .
Another European basis for the evaluation of environmental risks for use with applications for IVMPs can be seen in Directive 92/18 EEC. Objects of safety studies covered by this Directive include the spread of vaccine strains, dissemination in the body, reversion to virulence and the risk of recombination. The risk assessment for new vaccine strains to be registered must normally be conducted in two phases. Only if the conclusions of the first phase indicate potential exposure of the environment to the product must the applicant proceed to the second phase and evaluate the potential ecotoxicity of the product. Several parameters must be tested, with the help of validated methods. For qualitative risk assessments, many models are in use in the laboratories (Table III) . 
METHODS AND MODELS OF RISK ASSESSMENTS
As mentioned above, accepted and validated control methods and risk indicator systems form part of suitable models of qualitative risk assessments (1) . Often, these have been established for many years. In vivo animal systems can be distinguished from in vitro cell-culture systems (Fig. 2) .
To create a new model, it is necessary first to identify the object, i.e. where the potential hazard occurs. Furthermore, the principles of containment include biological Indicator systems used in risk assessment models for biologicals containment and physical containment. For biological containment, barriers exist naturally and limit the distribution of GMOs, non-GMOs and BRMs. Physical containment is characterised by equipment, operating practices and techniques, e.g. good laboratory practice (GLP) and good manufacturing practice (GMP). European rules relating to this field are European Council Directive 88/320 EEC of 9 June 1988 on the inspection and verification of GLP, and European Commission Directive 91/412 EEC of 23 July 1991, which lays down the principles and guidelines of GMP for veterinary medicinal products. These European rules are legal barriers with an indirect influence on the risk associated with the use of veterinary biologicals. Several indicators are used to control such biological, physical, geographic and legal barriers (Table IV) .
It is essential that new IVMPs prepared for the European market be released in stages, and that a risk assessment be conducted. For the field trial period and for the later commercial application, a system of 'pharmaco-vigilance' is necessary (Table V) .
During the various steps in the release of live GMOs, non-GMOs and BRMs which replicate well, risk differences exist between non-zoonoses and zoonoses. Scala (6) defines risk as 'the probability of a particular adverse effect' on human health. For zoonoses, the highest human risks for staff exist during the contained application and during early laboratory experiments, whereas the highest risks for target and non-target animals exist during the field test period and the first months of commercial application (Table VI) .
The deliberate release of live GMOs, non-GMOs and BRMs into the environment must be combined with an estimation of the risks involved in proceeding to the next step. For example, the genetic stability of a new vaccine strain is demonstrated with the help of reverse passages and susceptible tissue cultures, eggs or animals (Fig. 3) . 
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In the case of a deliberate release of live carrier viruses (e.g. vaccinia-vectored rabies virus vaccine), the models used for qualitative risk assessment in the laboratory can be distinguished from animal models used in the field. It should be considered that the tenacity of vaccinia virus is quite high. Consequently, the vaccinia carrier in rabies live vaccines for foxes has a long-lasting activity. Therefore, the risks for non-target humans with an allergic or atopic case history should not be neglected (Fig. 4) .
EUROPEAN PHARMACOPOEIA
The EP monograph 'Freeze-dried Aujeszky's disease live vaccine for pigs for parenteral administration' can be considered as an example of models for qualitative risk assessments described by the EP. According to the definition given in the 
GMO: genetically-modified organism
Step 2: Field application
Steps of deliberate release of live organisms into the environment Combined in vitro/in vivo model using reverse passages Risk differences between non-zoonoses and zoonoses during release steps Used in step-by-step approach for risk assessment during development of biological products and inducers for more than one species, using an animal model (main species to be vaccinated)
Step 1 The animals used for the various tests, their age, the route of administration and the observation period must be determined in connection with the 'Instructions for use' of the vaccine after registration (Table VII) . 
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